Eagle's Eye View: Your Weekly CV Update From ACC.org
The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
Episodes
Sex Disparities in CV Trials; Left Stellate Ganglion Blocks & CABG; Bifurcation Lesions; Managing Resistant Hypertension
In this week's View, Dr. Eagle looks at continued sex disparities in CV clinical trials. He then examines how preemptive left stellate ganglion block (SGB) is associated with a reduced incidence of postoperative atrial fibrillation (POAF) in patients undergoing CABG. He follows that with a look at bifurcation lesions as analyzed in the OCTOBER Trial. Finally, Dr. Eagle offers a brief vignette on r
ACC/AHA Joint Perioperative Guidelines; Atenolol and MACE Risk; Yoga and VPCs; DECIPHER and CMR
In this week's View, Dr. Eagle looks at how the most recent perioperative guideline published in 2024 remains valid and current. He then examines how, in the treatment of patients without recorded heart failure (HF), starting atenolol after a myocardial infarction (MI) was associated with a lower two-year risk of major adverse cardiovascular events (MACE), but not all-cause mortality. He follows
Whole Grain Intake & CV Health, Talfamidis & Recurrent Cardiovascular Events, Revascularization & Improved Cognition, Coronary Blood Flow in Women
In this week's View, Dr. Eagle looks at how higher whole-grain intake was associated with improvements in multiple cardiometabolic risk factors in a meta-analysis of randomized trials. He then examines how concomitant use of tafamidis or heart failure (HF) therapies did not modify the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events, according to a HELIOS
First Medical Contact, CV Toxicity and Antibody-Drug Conjugates, Extreme Heat & Blood Pressure, FinACAF & Lower Risk of ischemic Stroke
In this week's View, Dr. Eagle looks at a recent JACC: Advances Viewpoint that examines the challenges associated with implementing revisions to the definition of first medical contact (FMC) introduced in the 2025 ACC/AHA ACS Guideline and its implications for NCDR data collection. He then examines a cardiooncology primer on CV toxicity of antibody-drug conjugates (ADCs) in breast cancer and foll
CV Subspecialty Training; a Novel Left Atrium Staging Framework; the (IL)-6 Inflammatory Biomarker, HF Risk & Diabetes
In this week's View, Dr. Eagle looks at a recent article on proposed changes to the current cardiovascular (CV) subspecialty training path. He then examines an article on a novel left atrium (LA) staging framework that stratifies new-onset atrial fibrillation risk in hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle explores the results of a Look AHEAD ancillary study on the inflammatory biom
Top Five Trials from ESC 26: SINGLE-AF, REBOOT-PARADOX, ViVA, REACT, NOTION-4
In this week's View, Dr. Eagle looks at some of the important trials presented at this year's European Society of Cardiology (ESC) Congress. First, he evaluates the SINGLE-AF trial on DOAC therapy versus no anticoagulation in atrial fibrillation (AFib) with patients with intermediate stroke risk. Dr. Eagle then examines REBOOT-PARADOX and its study of the potential value of transcatheter aortic v
M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM.
In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) a
: M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM.
In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) a
CAC, CRF & Dementia; Athletes & Arrhythmia; Vutrisaran & Amyloid Burden; NT0proBNP Screening & Heart Failure
In this week's View, Dr. Eagle looks at the relationship between lower cardiorespiratory fitness (CRF) and higher coronary artery calcium scores (CAC) and later-life dementia. He follows this with a look at a new State of the Art Review related to guidance on treating athletes with arrhythmia. He then offers a perspective on the use of vutrisiran in the treatment of amyloid burden. Finally, Dr.
Antithrombotic Regimens after Valve-in-Vave TAVR; TAV vs. SAVR Outcomes in Low-Risk Patients; Sex Difference and Delayed Diagnosis on Acoramidis; Lifestyle Intervention and ANOCA
In this week's View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on TAVR versus surgical aortic valve replacement (SAVR) outcomes in low-risk patients. He then offers a perspective on the effect of sex difference and delayed diagnosis in patients with transthyretin
Venous Thromboembolism & Cancer; Influenza Vaccines & AFib; the DAPT-MVD Trial & Cutting PCI in CAD; the AC Expect Consensus Decision Pathway on HFpEF
In this week's View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis. He follows with a look at an observational cohort study on how influenza vaccination is associated with lower risks of incident atrial fibrillation (AFib), then re
Age, BMI, & TAVR; Enhanced Radiation Protections in Cath Labs; Particulate Matter and CV Risk; the SUMMIT Trial & Tirzepatide.
In this week's View, Dr. Eagle looks at age, body mass index (BMI), and cardiovascular outcomes after transcatheter aortic valve replacement (TAVR). He follows this with an examination of a new consensus statement about enhanced radiation protection in cath labs, then offers a perspective on particulate matter in the environment and increased coronary heart disease risk. Finally, Dr. Eagle provid
Mechanical Leaflet Splitting and TAVR; Ambient Temperature & Marathons; AFib, PVI with PA & IRF; the SHaRE Registry as a Predictor of MACE
In this week's View, Dr. Eagle looks at the feasibility of mechanical leaflet splitting in high-risk patients undergoing valve-in-valve TAVR. He follows this with an examination of lower ambient temperature and it association with greater SCA risk at marathon races, then offers a commentary on two studies that provide new insights on the durability of pulmonary vein isolation (PVI) with pulsed fie
Guideline-Directed Medical Therapy & Atrial Fibrillation; Anti-Platelet Therapy & ASCVD; DOACs & Prevention of Thrombotic Events; Sugar-Sweetened Beverages and Fruit Juice & Hypertension
In this week's View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF). He follows this with commentary on two important recently released ACC scientific statements: one on anti-platelet therapy for atherosclerotic cardiovascular disease (ASCVD), and the other examining the use of direct oral anticoagulants (DOACs) for primary and
Genotype and Hypertrophic Cardiomyopathy; PARTNER 2A & TAVR 10 Years Later; Clopidogrel vs. Aspirin after PCI; LDL & Risk Assessment of ASCVD
In this week's View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). He then examines the ten-year follow-up of the PARTNER 2A trial and compares the transcatheter aortic valve replacement (TAVR) outcomes to results from the Partner 2 SAPIEN XT and SAPIEN 3 studies. He follows this with a report on how clopidogrel m
Lifestyle Intervention, Metformin and Multimorbidity Risk in Prediabetes; Hypertension, Hyperlipidemia and Chronic Kidney Disease, Resistance Training & Myocardial Infarction
In this week's View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. He also highlights low rates of hypertension and hyperlipidemia treatment among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, and summarizes evidence that resistance training,
Race and Sex Disparities in Mitral Valve Edge-to-Edge Repair
In this week's View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. He reviews the SOGALDI-PEF trial, where patients with low plasma renin levels experienced greater blood pressure redu
Impact of Semaglutide And Survival Outcomes In Patients With T2D and CKD
In this week's View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care. He first examines the FLOW analysis, underscoring the benefits of semaglutide for patients with chronic kidney disease, with particular attention to its impact on both renal and cardiovascular outcomes. He then reviews a phase I study exploring an innovative therapeutic approach involvi
Postpartum Cardiovascular Care; 'Low Risk' Chest Pain in the ER; Heart Failure Risk Detection & CV Outcomes with Implantable Devices
In this week's View, Dr. Eagle looks at recent research found in ACC's new expert decision pathway for postpartum cardiovascular care. He then offers insights from the ACC Chest Pain - MI Registry examining 'low risk' chest pain and its evaluation in the emergency departments. Next, a discussion of how negative patient outcomes were associated with late pericardial effusion post-left atrial appen
Maintaining Weight Loss with Tirzepatide; the new Dyslipidemia Guidelines; Sacubitril/Valsartan & HFpEF & Functional MR; Digitoxin & Heart Failure
In this week's View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. Next, Dr. Eagle looks at the use of sacubitril/valsartan to improve exercise tolerance in patients with heart failure with reduced ejection
HCM, NT-proBNP and HCM Risk Evaluation; Arrhythmic Burden in Cardiac Amyloidosis Obesity and Heart Failure; Postural Orthostatic Tachycardia Syndrome (POTS)
In this week's View, Dr. Eagle reviews evidence supporting the use of cardiac magnetic resonance (CMR) and NT-proBNP in hypertrophic cardiomyopathy (HCM) risk assessment. He then examines the EXCALIBUR study, which aims to better characterize arrhythmic burden in patients with cardiac amyloidosis. Next, he discusses research identifying obesity as a significant risk factor for heart failure, high
Rhythm Control & Tricuspid Valve Regurgitation; Benefits of Blood Pressure Control on Cardiovascular Disease; Switching DOAC Therapy in AFIB Patients with Stroke; Pulsed Field Ablation & Persistent AFib
In this week's View, Dr. Eagle examines the role of rhythm control in improving moderate-to-severe and severe secondary tricuspid valve regurgitation. He then explores evidence showing that blood pressure reduction can deliver comparable cardiovascular benefits for patients with chronic kidney disease (CKD). Another study reviewed in this episode assesses the outcomes of continuing versus switchi
Pulsed Field Ablation and PAS; TRIDENT & Antihypertensive Polypharmacy; NOBLE and PCI vs. CABG
In this week's View, Dr. Eagle looks at the NOBLE trial evaluating whether percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is best for patients with unprotected left main coronary artery disease (CAD). He then explores a report highlighting nanosecond pulsed field ablation (nsPFA) and its safety and efficacy at one year for paroxysmal atrial fibrillation. Finall
Benefits of Endovascular Therapy for Post-Thrombotic Syndrome; Sex Hormones & CV Risk; Asundexian & Stroke Risk; Cardiorespiratory Fitness & Longer Lifespans
In this week's View, Dr. Eagle looks at endovascular therapy for post-thrombotic syndrome and how it reduces severity and improves quality of life. He then explores current evidence and strategies to address sex hormone-associated thrombotic and cardiovascular risk. Next, Dr. Eagle examines the OCEANIC-STROKE trial which studied asundexian and its potential to lower recurrent stroke risk in patie
Early Surgery for AS; Blood Pressure Trajectories; PCI vs Medical Therapy for Chronic Coronary Disease
In this week's View, Dr. Eagle examines early surgery for asymptomatic patients with severe aortic stenosis. He then reviews evidence linking blood pressure trajectories and rapid control to significantly improved outcomes. Finally, he compares percutaneous coronary intervention with medical therapy for chronic total occlusion in patients with chronic coronary disease. Subscribe to Eagle's Ey
Caring for Patients: Cardiogenic Shock Survivorship, Masters Athletes, Medicare Spending on Semaglutide, GDMT and Veterans
In this week's View, Dr. Eagle explores four recent articles that examine how we care for patients. First, Dr. Eagle looks at a new state-of-the-art review that outlines a multidisciplinary framework for cardiogenic shock survivorship. He then analyzes the new Joint Clinical Statement focusing on Masters athletes with abnormal cardiovascular findings, followed by details on a study of how partic
Top Takeaways from ACC.26
In this week's View, Dr. Eagle highlights trials from the recently held ACC Scientific Sessions which took place in New Orleans, March 28-30. Important studies discussed include: CHAMPION-AF: Left atrial appendage closure vs. anticoagulation for AFib VESALIUS-CV: Evolocumab reduces CV risk in diabetic patients without ASCVD Ez-PAVE: Hitting lower LDL-C target reduces major CV
New ACC/AHA Dyslipidemia Guidelines Released
In this week's View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off-label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. He then explores the REVNOVATE-COMPLEX-PCI study that investigates the benefits of intravascular imaging guidance for five years. Finally, Dr. Eagle summarizes the ACC/AHA's newly rele
Beta-Blocker vs. Calcium-Channel Blocker in HCM
In this week's View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) hospitalization risk in patients with type 2 diabetes, comparing GLP-1RAs to DPP-4 inhibitors and similar outcomes with SGLT-2 inhibitors. Dr. Eagle then examines the use of shared decision-making an
Increased Mortality and TAVR; Wine Intake and CV Risk; PVI & Drug-Refractory Paroxysmal Atrial Fibrillation
In this week's View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR). He then explores the PREDIMED trial which found that adherence to the Mediterranean diet plus moderate wine intake was associated with reduced cardiovascular risk and mortality. Finally, Dr. Eagle examines 20-year outcomes for pulmonary vein isolation
Self-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism
In this week's View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. He then explores the TUXEDO-2 Trial evaluating ticagrelor versus prasugrel in percutaneous coronary intervention patients with diabetes and multivessel coronar
ORBITA-2 & PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF
In this week's View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. He then explores the EQUAL trial that investigated how Apple smartwatch monitoring improves atrial fibrillation (AFib) detection. Finally, Dr. Eagle examines revelations from the EMPEROR-Preserved trial regarding interaction between SGLT2
Exercise Testing & Systolic Blood Pressure; the Navitor TAVR valve; the ABILITY Diabetes Global Trial & Stent Comparisons for People with Diabetes
In this week's View, Dr. Eagle looks at exercise systolic blood pressure (SBP) during stress testing related to cardiovascular (CV) events. He then explores the novel Navitor transcatheter heart valve (THV) and its safety and effectiveness in younger patients requiring transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle examines the value of 18F-FAPI PET/CT imaging and its role in a
The State of CV Health in the US; Semaglutide and Reduced Hospital Admissions; D-Dimer and Its Use in Ruling Out DVT
In this week's View, Dr. Eagle comments on the recently published JACC Cardiovascular (CV) Statistics report which evaluates the management of CV risk factors in the United States. He then explores the use of semaglutide and its association with reduced hospital admissions and length of stay. Finally, Dr. Eagle examines the multicenter, multinational ADJUST-DVT study on the age-adjusted use of D-
Reducing Fat & Reducing Mortality & Stroke; Tirzepatide s. Dulaglutide; Finerenone and Hypotension; Low Operator Volume and Worse Outcomes
In this week's View, Dr. Eagle evaluates the impacts that reducing saturated fat have on mortality, nonfatal myocardial infarction (NFMI), and stroke in high-risk individuals. He then explores the SURPASS-CVOT study which considers if tirzepatide is superior to dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Next, he summarizes the FINEARTS-HF stud
Eagle's Eye View: Top 2025 ACC Content
In this episode, Dr. Eagle looks back at 2025 and explores some of the significant developments that show how the College is responding to changes in the way we evaluate, manage, and follow patients with various types of cardiovascular disorders. His survey of topics that received the most attention include the new guidelines on hypertension, acute coronary syndromes, the management of adults wit
Weight Reversal Post Tirzepatide Withdrawal
In this week's View, Dr. Eagle looks at the DANISH trial extended follow-up, evaluating which patients benefit most from primary prevention implantable cardioverter defibrillator (ICD) implantation. He then explores the SURMOUNT-4 study on weight reversal post tirzepatide withdrawal. Finally, Dr. Eagle examines two JACC articles that cover disease monitoring: one tracking the progression of trans
The PREVENT Equations & Cardiovascular Risk, the CREST-2 Trials on Carotid Disease , Physician Burnout, Food Labeling & CV Health
In this week's View, Dr. Eagle looks at the use of PREVENT equations to assess cardiovascular (CV) disease risk and the CREST-2 randomized trials that examined stenting versus endarterectomy for asymptomatic carotid disease. He then explores physician burnout and the use of coaching to help treat it. Finally, Dr. Eagle explores how clearer, "front of package" food labeling in grocery stores can
Improving The Culture and Climate Surrounding Cardiology
In this week's View, Dr. Eagle looks at the potential for electrophysiology (EP) ablation in ambulatory care. He then explores several new studies that reveal the rising rates of heart failure and hypertension. Finally, Dr. Eagle discusses a very important new survey from ACC on the need to improve the professional climate and culture for US cardiologists and trainees. Subscribe to Eagle's Ey
Gastrointestinal Bleeding After LAAO, Lifestyle Modification & Metabolic Syndrome, Beta-Blockers & the Treatment of Preserved LVEF
In this week's View, Dr. Eagle looks at gastrointestinal bleeding (GIB) after left atrial appendage occlusion (LAAO). He then explores lifestyle modifications to treat metabolic syndrome. Finally, Dr. Eagle examines a recent study which found that beta-blockers failed to reduce death, myocardial infarction (MI) or heart failure (HF) in patients with preserved left ventricular ejection fraction
Eagle's Eye View: Highlights from the 2025 AHA Scientific Sessions
In this week's View, Dr. Eagle highlights several important studies presented at the recent American Heart Association Scientific Sessions. The OCEAN Trial on antithrombotic and stroke prevention in patients with atrial fibrillation (AFib). He then explores VESALIUS-CV, a study on evolocumab versus placebo in patients with atherosclerosis or diabetes and without previous myocardial infarction (MI
Highlights From 2025 TCT Conference
In this week's View, Dr. Eagle highlights several trials recently presented at the TCT Conference in San Francisco. The SELUTION DeNovo trial found that use of the sirolimus-eluting balloons with bailout stenting only if necessary was noninferior to routine drug-eluting stent implantation in patients with de novo coronary artery disease. In the ANDES trial, results showed that the use of direct o
Aspirin, Anticoagulants, & Chronic Coronary Disease; Perioperative Blood Pressure Management; High-Dose Flu Vaccines & Hospitalizations
In this week's View, Dr. Eagle looks at a study comparing the use of aspirin and oral anticoagulants versus anticoagulants alone in the treatment of chronic coronary disease (CCD). He then explores complications after noncardiac surgery and the efficacy of perioperative blood pressure management. Finally, Dr. Eagle discusses FLUNITY-HD, a study comparing high-dose flu vaccines to standard dose
Heart Disease Mortality in California; Pregnant Women and Cardiometabolic Comorbidities; CABG and New-Onset AFib
In this week's View, Dr. Eagle looks at the social drivers behind the rise in heart disease mortality in California. He then explores the prevalence of preexisting cardiometabolic comorbidities and cardiovascular disease among pregnant women. Finally, Dr. Eagle discusses a recent prospective cohort study of patients who undergo coronary artery bypass graft (CABG) and experience new-onset atrial f
Evidence and Innovations Targeting Inflammation Post-AMI
In this week's View, Dr. Eagle looks at the potential value of sodium-glucose cotransporter 2 (SGLT2) agents after transcatheter aortic valve implantation (TAVI). He then explores a new randomized trial, HYPERION, focusing on the addition of sotatercept to lower the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses a state-of-the-art r
A Look at ACC's Scientific Statement on Inflammation and CVD
In this week's View, Dr. Eagle looks at an ACC Scientific Statement highlighting inflammation and its role in cardiovascular disease (CVD). He then explores left atrial appendage occlusion (LAAO) in patients with prior intracranial hemorrhage or ischemic stroke. Finally, Dr. Eagle discusses the recently released NEWTON-CABG CardioLink-5 trial on the use of evolocumab in the reduction of saphenous
Oral Semaglutide for Weight Loss; Anticoagulants for PAH; The ECDP on TR Evaluation and Management
In this week's View, Dr. Eagle looks at the value of oral semaglutide for weight loss. He then explores whether anticoagulants improve survival in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses the recent release of the ACC Expert Consensus Decision Pathway (ECDP) on tricuspid regurgitation (TR) evaluation and management. Subscribe to Eagle's Eye View
Nonatherothrombotic Myocardial Infarction and SCAD in Younger Patients; the Benefit of Intensive Blood Pressure Control; Clopidogrel vs. Aspirin for Prevention of CV Events
In this week's View, Dr. Eagle looks at the net benefit of intensive blood pressure control between fewer cardiovascular and more adverse events. He then explores non-atherothrombotic myocardial infarction events and spontaneous coronary artery dissection (SCAD) in younger patients – something more commonly found among young women than young men. Finally, Dr. Eagle discusses whether clopidogrel i
Aspirin in PCI; Mavacamten in Nonobstructive Cardiomyopathy; Olezarsen and the Treatment of Hypertriglyceridemia
Dr. Eagle continues in this week's View to analyze some of the key clinical content presented at the ESC Congress recently held in Spain. Dr. Eagle examines the TARGET-FIRST trial in which P2Y12-inhibitor monotherapy was compared to dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). He then analyzes the results of the ODYSSEY-HCM trial which
Aficamten vs. Metoprolol for HCM; Beta Blocks and Myocardial Infarction (MI); Reconditioned Pacemakers for Improving Global CV Health
In this week's View, Dr. Eagle looks at major trials presented at the recent ESC Congress in Spain. First, he discusses the MAPLE-HCM trial that investigates aficamten versus metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). He then explores a set of important presentations on beta blocker therapy following myocardial infarction. Finally, Dr. Eagl
Self-Service Blood Pressure Kiosks; the FLAVOUR Trial & Intermediate Coronary Stenosis; CPAP & Cardiovascular Outcomes
In this week's View, Dr. Eagle evaluates the potential value of self-service blood pressure (BP) kiosks and their potential to improve hypertensive health nationwide. He then discusses the FLAVOUR trial and its comparable outcomes with fractional flow reserve (FFR) and intravascular ultrasound (IVUS)-guided treatment for intermediate coronary stenosis. Finally, Dr. Eagle explores how continuous p
New ACC/AHA Blood Pressure Guidelines; Right Angle Branch Blocks & Pacemakers; Gender-Affirming Care & Cardiac Repolarization
In this week's View, Dr. Eagle looks at the new ACC/AHA guideline for prevention, detection, evaluation and management of high blood pressure (BP). He then discusses new-onset right bundle branch block (RBBB) post-transcatheter aortic valve replacement (TAVR) and its association with a high risk of permanent pacemaker implantation (PPI). Finally, Dr. Eagle explores gender-affirming hormone therap
Compression Socks & Vasovagal Syncope; Management of Pericarditis; Early Cardiac Rehab for ADHF.
In this week's View, Dr. Eagle looks at whether compression stockings reduce vasovagal syncope recurrence. He then discusses new concise clinical guidance that addresses the evaluation and management of pericarditis. Finally, Dr. Eagle explores early, safe cardiac rehabilitation for critically ill patients hospitalized with acute decompensated heart failure (ADHF). Subscribe to Eagle's Eye Vi
BMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement
In this week's View, Dr. Eagle looks at the SUMMIT trial and considers how body mass index (BMI) and central adiposity affect tirzepatide outcomes for heart failure with preserved ejection fraction (HFpEF). He then discusses bicuspid aortic valves type 0 (BAV-0) and its association with better long-term prognosis in patients with severe aortic stenosis (AS) undergoing tricuspid aortic valve repla
BMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement
In this week's View, Dr. Eagle looks at the SUMMIT trial and considers how body mass index (BMI) and central adiposity affect tirzepatide outcomes for heart failure with preserved ejection fraction (HFpEF). He then discusses bicuspid aortic valves type 0 (BAV-0) and its association with better long-term prognosis in patients with severe aortic stenosis (AS) undergoing tricuspid aortic valve repla
The PREVENT Model & Risk Prediction; Carbohydrate Quality & Improved LV Structure; Radial Access for PCI & Lower Complication Rates
In this week's View, Dr. Eagle looks at the PREVENT model and its ability to predict ten-year atherosclerotic cardiovascular disease risk in diverse populations. He then discusses higher carbohydrate quality and fiber-rich foods and their links to better cardiac structure and function. Finally, Dr. Eagle explores increased use of radial access for percutaneous coronary intervention to achieve low
AV after TTVR; Deep Learning in Automating Cardiac IMG; Survival Benefits Post-2018 Heart Transplantation Policy Change
In this week's View, Dr. Eagle looks at predictors of high-grade atrioventricular block (AV) after transcatheter tricuspid valve replacement (TTVR). He then discusses the challenges and benefits of deep learning in automating cardiac imaging (IMG). Finally, Dr. Eagle explores higher survival benefits after the 2018 U.S. Heart Transplantation Allocation policy change. Subscribe to Eagle's Eye
Ischemic Preconditioning & Noncardiac Surgery; The Microaxial Flow Pump in STEMI-CS; DOACs After Strokes
In this week's View, Dr. Eagle looks at whether ischemic preconditioning provides benefit in noncardiac surgery. He then discusses the benefits of the microaxial flow pump in STEMI-cardiogenic shock (CS) patients undergoing hemodynamic monitoring. Finally, Dr. Eagle explores starting direct oral anticoagulants (DOACs) early after stroke, and whether it lowers the risk of future strokes and hemor
Frailty Status and Mortality Risk in PCI; Delays in Treatment in STEMI; Arterial Events with Genetic-based Vascular Disease
In this week's View, Dr. Eagle looks at frailty status and increased risk of mortality in patients who undergo percutaneous coronary intervention (PCI). He then discusses the timely treatment and delays in treatment of ST-segment elevation myocardial infarction (STEMI) that are associated with worse outcomes. Finally, Dr. Eagle explores new insights on arterial events associated with heritable th
LAAO and the Watchman FLX; HF Care in Private Equity Hospitals; Long-term Outcomes in TR and Mitral Valve-in-Valve Replacement
In this week's View, Dr. Eagle looks at the lower risk of major adverse events in patients with left atrial appendage occlusion (LAAO) using the Watchman 2.4 device. He then discusses the impact of heart failure (HF) care in private equity hospitals in the United States. Finally, Dr. Eagle explores the long-term outcomes of patients with tricuspid regurgitation (TR) undergoing mitral valve-in-val
Marijuana Use & Endothelial Function; CV & Bleeding With Aspirin v. Clopidogrel; Mental Health for Survivors of SCA and ICD Shock
In this week's View, Dr. Eagle looks at chronic marijuana smoking and THC-edible use and its impairment of endothelial function. He then discusses the cardiovascular (CV) and bleeding effects of aspirin versus clopidogrel in patients with acute coronary syndromes. Finally, Dr. Eagle explores the importance of addressing mental health symptoms in survivors of sudden cardiac arrest (SCA) who experi
Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension
In this week's View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol's effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hyper
Colchicine vs. Placebo in Reducing CV Events; DOACs vs. Warfarin After TAVR; CSP vs. BiVP and Echo Response
In this week's View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus
ORBITA-2 & PCI; Blood Pressure Control & Increasing Medication Prescriptions; Rapid Initiation & Titration in GRMT for Patients with HFrEF
In this week's View, Dr. Eagle looks at the results of the ORBITA-2 Trial and its use in stress echocardiography before PCI. He then discusses the proportion of patients achieving blood pressure (BP) control plateaus despite increasing medication prescriptions. Finally, Dr. Eagle explores the use of rapid initiation and titration in guideline-recommended medical therapy (GRMT) in patients with he
Lp(a) and CV Risk; CRP Levels and High-Risk Vulnerable Plaque post-NSTEMI; Pulsed Field Ablation vs. Cryoablation for Paroxysmal AFib
In this week's View, Dr. Eagle looks at Lp(a) levels and cardiovascular (CV) risk. He then discusses the potential value of high-sensitivity C-reactive protein (hsCRP) in identifying high-risk and more vulnerable plaque in patients after non-ST-segment elevation myocardial infarction (STEMI). Finally, Dr. Eagle explores pulsed field ablation versus cryoablation for paroxysmal atrial fibrillation
Weight Management in Pregnancy and CVD Risk; Impact of Statins Plus Ezetimibe Post-MI; PARTNER-3 Study 5-year Results
In this week's View, Dr. Eagle examines weight management in pregnancy related to cardiovascular disease (CVD) risk. He then considers how the addition of early ezetimibe to statin could reduce CVD after myocardial infarction (MI). Finally, Dr. Eagle explores the PARTNER-3 study results which compare transcatheter aortic valve replacement (TAVR) to surgical aortic valve replacement (SAVR) and the
Outcomes of Pre-ablation Transesophageal Echocardiograms; TAVI vs. SAVR in Women With Severe AS; Effects in the Use of Oral Anti-coagulants (OACs)
In this week's View, Dr. Eagle examines the effects on patients who have undergone pre-ablation transesophageal echocardiogram (TEE) versus those who have not. He then discusses a recent paper investigating the superiority of transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR) at one year in women with severe aortic stenosis (AS). Finally, Dr. Eagle explores
Key Takeaways from ACC.25 Major Trials and Presentations
In this week's View, Dr. Eagle looks at the major trials and presentations from the recently concluded ACC.25 in Chicago. This episode includes coverage of practice-changing and practice-validating trials including: Evolut Low Risk: Transcatheter aortic valve replacement (TAVR) noninferior to surgical aortic valve replacement (SAVR) at 5-Year Follow-Up SMART-CHOICE 3: Clopidogrel sh
Cardiogenic Shock Guidance; Mortality after Mitral Repair & TAVR; Direct-to-Physician Marketing Affects GDMT
In this week's View, Dr. Eagle looks at the latest clinical guidance on the management of cardiogenic shock. He then discusses trends in mortality after mitral repair and TAVR. Finally, Dr. Eagle offers a brief exploration into how direct-to-physician industry marketing affects rates of guideline-directed medical therapy (GDMT) surrounding heart failure patients. Subscribe to Eagle's Eye Vie
Smoking & CVD Risk; Sleep, Diabetes, & Women with Gestational Diabetes; Post-TAVR Imaging
In this week's View, Dr. Eagle examines the dose-response relationship between smoking and subclinical cardiovascular disease markers. He then discusses how the effect of poor sleep increases diabetes risk in women who have had gestational diabetes. Finally, Dr. Eagle offers a look into imaging post-transcatheter aortic valve replacement (TAVR) in patients who may have valve failure. Subscri
Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin & Heart Failure; Non-Pharmacologic Treatment of HF
In this week's View, Dr. Eagle looks at a sex-based analysis of short-term dual antiplatelet therapy (DAPT) in patients receiving percutaneous coronary intervention (PCI) who are deemed at high-risk for bleeding. He then discusses the potential value of dapagliflozin in patients with severe heart failure (HF). Finally, Dr. Eagle explores non-pharmacologic therapies to reduce morbidity and improve
Identifying Myocardial Infarction after PCI; Myocardial Fibrosis & Severe Aortic Valve Stenosis; Anticoagulation & Cancer Diagnoses
In this week's View, Dr. Eagle looks at the optimal threshold for identifying a myocardial infarction (MI) after PCI. He then discusses myocardial fibrosis and its prognostic features in patients undergoing treatment for severe aortic valve stenosis. Finally, Dr. Eagle explores the relationship between bleeding after initiation of anticoagulation and cancer diagnoses. Subscribe to Eagle's Eye
SGLT2 Inhibitors & Aortic Valve Stenosis; Early vs. Later Ablation for Afib; Sports Participation by Athletes with Cardiac Abnormalities
In this week's View, Dr. Eagle looks at the potential exposure-dependent protective effect of SGLT2 inhibitors on aortic valve stenosis progression. He then discusses the potential value of earlier ablation for atrial fibrillation versus later ablation. Finally, Dr. Eagle explores new guidance for sports participation by athletes with cardiac abnormalities. Subscribe to Eagle's Eye View
Arrhythmia Recurrence & Rhythm Control after Catheter Ablation for AFib; Transthyretin Amyloid Cardiomyopathy & Tafamidis; Sodium Restriction & BP
In this week's View, Dr. Eagle looks at arrhythmia recurrence and rhythm control after catheter ablation for atrial fibrillation. He then discusses long-term outcomes in transthyretin amyloid cardiomyopathy in patients treated with tafamidis. Finally, Dr. Eagle explores a population study on the effect of sodium restriction in food and its potential effects on blood pressure. Subscribe to Eag
Blood Pressure & Postpartum; Beta Blockers & Takotsubo Syndrome; Secondary Prevention Worldwide
In this week's View, Dr. Eagle looks at tighter blood pressure control in patients who are postpartum. He then discusses beta blocker therapy in patients with Takotsubo syndrome. Finally, Dr. Eagle explores secondary prevention and medications around the world. Subscribe to Eagle's Eye View
Cardiac Rehab & Heart Failure, CV Care & Cancer Survivors, Bioprosthetic AVR vs Mechanical AVR in Younger Patients
In this week's View, Dr. Eagle looks at cardiac rehabilitation for people with heart failure. He then discusses managing cardiovascular (CV) disease in cancer survivors who have completed cancer therapy. Finally, Dr. Eagle explores bioprosthetic aortic valve replacement (AVR) versus mechanical AVR in younger patients. Subscribe to Eagle's Eye View
Cost-effectiveness of Polypills, Obesity and FH, Adverse Pregnancy Outcomes and Long-term HF Risk
In this week's View, Dr. Eagle examines the cost-effectiveness of polypills. He then discusses overweight and obesity in patients with familial hyperlipidemia. Finally, Dr. Eagle explores how adverse pregnancy outcomes are associated with long-term risk of heart failure. Subscribe to Eagle's Eye View
Left Atrial Appendage Occlusion & Stroke, Hypertrophic Cardiomyopathy in Children, Anticoagulation & COVID-19
Top Trials, Journal Scans, and Takeaways of 2024
In this week's special edition of Eagle's Eye View, Dr. Eagle looks at the top trials, journal scans, and clinical developments in cardiology that have changed your practice and will continue to change clinical care in the future. Subscribe to Eagle's Eye View
What Cardiologists Should Know About Congenital Heart Disease, Cardiac Arrest and Death in Athletes, Arrhythmia After Stroke
In this week's View, Dr. Eagle looks at what adult cardiologists should know about congenital heart disease patients. He then discusses sudden cardiac arrest and death in competitive and recreational athletes. Finally, Dr. Eagle explores practical approaches for arrhythmia monitoring after stroke. Subscribe to Eagle's Eye View
